Zoetis Inc. $ZTS Position Lessened by DAVENPORT & Co LLC

DAVENPORT & Co LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 51.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,244 shares of the company’s stock after selling 18,638 shares during the period. DAVENPORT & Co LLC’s holdings in Zoetis were worth $2,171,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Halbert Hargrove Global Advisors LLC increased its position in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $32,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.7%

Shares of ZTS stock opened at $113.48 on Friday. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The firm’s fifty day simple moving average is $123.39 and its 200 day simple moving average is $129.17. The firm has a market capitalization of $47.90 billion, a P/E ratio of 18.85, a price-to-earnings-growth ratio of 1.73 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis’s payout ratio is currently 35.22%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ZTS shares. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Barclays began coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.